Devonian Health Group Inc (GSD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Devonian Health Group Inc (GSD) has a cash flow conversion efficiency ratio of -0.675x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-5.33 Million ≈ $-3.86 Million USD) by net assets (CA$7.90 Million ≈ $5.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GSD cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Devonian Health Group Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Devonian Health Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Devonian Health Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Devonian Health Group Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GREMI MEDIA S.A. ZY 4
F:4C8
|
0.076x |
|
Image Resources NL
AU:IMA
|
0.024x |
|
OB Holdings Berhad
KLSE:0327
|
-0.040x |
|
Cliq Digital AG
F:CLIQ
|
0.212x |
|
Pion Group AB Series B
ST:PION-B
|
-0.103x |
|
The Brand House Collective, Inc.
NASDAQ:TBHC
|
0.589x |
|
Rocketdna Ltd
AU:RKT
|
-0.192x |
|
Bankers Investment Trust
LSE:BNKR
|
0.029x |
Annual Cash Flow Conversion Efficiency for Devonian Health Group Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Devonian Health Group Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Devonian Health Group Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-07-31 | CA$9.14 Million ≈ $6.61 Million |
CA$-1.25 Million ≈ $-902.62K |
-0.137x | -133.55% |
| 2024-07-31 | CA$13.86 Million ≈ $10.03 Million |
CA$5.64 Million ≈ $4.08 Million |
0.407x | +233.12% |
| 2023-07-31 | CA$14.25 Million ≈ $10.31 Million |
CA$-4.36 Million ≈ $-3.15 Million |
-0.306x | -73.26% |
| 2022-07-31 | CA$16.27 Million ≈ $11.77 Million |
CA$-2.87 Million ≈ $-2.08 Million |
-0.176x | +27.58% |
| 2021-07-31 | CA$7.52 Million ≈ $5.44 Million |
CA$-1.83 Million ≈ $-1.33 Million |
-0.244x | -12.78% |
| 2020-07-31 | CA$9.38 Million ≈ $6.79 Million |
CA$-2.03 Million ≈ $-1.47 Million |
-0.216x | -88.03% |
| 2019-07-31 | CA$10.08 Million ≈ $7.29 Million |
CA$-1.16 Million ≈ $-837.62K |
-0.115x | +31.72% |
| 2018-07-31 | CA$12.74 Million ≈ $9.21 Million |
CA$-2.14 Million ≈ $-1.55 Million |
-0.168x | +43.31% |
| 2017-07-31 | CA$8.19 Million ≈ $5.92 Million |
CA$-2.43 Million ≈ $-1.76 Million |
-0.297x | +42.78% |
| 2016-07-31 | CA$4.13 Million ≈ $2.99 Million |
CA$-2.14 Million ≈ $-1.55 Million |
-0.519x | -84.91% |
| 2015-07-31 | CA$5.19 Million ≈ $3.75 Million |
CA$-1.46 Million ≈ $-1.05 Million |
-0.281x | -- |
About Devonian Health Group Inc
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis as… Read more